Effects of apolipoprotein C-II (apoC-II) on the lipolysis of very low density lipoproteins from apoC-II deficient patients.
D000293:Adolescent; D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001053:Apolipoproteins / Q000097:blood / Q000172:deficiency* / Q000494:pharmacology; D001056:Apolipoproteins C; D003619:Dansyl Compounds; D005260:Female; D005456:Fluorescent Dyes; D006801:Humans; D007700:Kinetics; D008066:Lipolysis / Q000187:drug effects*; D008071:Lipoprotein Lipase / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000097:blood* / Q000378:metabolism; D008297:Male; D010714:Phosphatidylethanolamines; D014280:Triglycerides / Q000378:metabolism
D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001053:Apolipoproteins; D001056:Apolipoproteins C; D003619:Dansyl Compounds; D005456:Fluorescent Dyes; D008079:Lipoproteins, VLDL; D010714:Phosphatidylethanolamines; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; C024284:dansyl phosphatidylethanolamine; D008071:Lipoprotein Lipase